Welcome to our dedicated page for Biomerica news (Ticker: BMRA), a resource for investors and traders seeking the latest updates and insights on Biomerica stock.
Biomerica reports developments in diagnostic-guided therapies and medical diagnostic products used in point-of-care, home, physician-office and clinical laboratory settings. The company focuses on gastrointestinal and inflammatory diseases, with recurring updates around inFoods® IBS, a finger-stick blood test used to identify individual food triggers for IBS dietary guidance, and Hp Detect™/hp+detect™, an H. pylori stool antigen diagnostic.
Biomerica news also covers commercialization and regulatory activity for products such as EZ Detect™, an at-home colorectal disease screening test, along with international distribution, laboratory partnerships, reimbursement and coding updates, clinical data presentations, fiscal results and the company’s CDMO services activity.
Biomerica has launched a new high-volume production test for COVID-19 IgG/IgM, receiving CE mark approval. This rapid test, requiring only a finger prick and yielding results in 10 minutes, is designed for international markets, with a unit price of $10. The company has started shipping this test to distributors serving NATO and government agencies in Germany, Switzerland, and the Netherlands. Additionally, Biomerica is expanding its patent applications for a simplified blood sample collection method for future tests, aiming to meet international demand while remaining environmentally friendly.